Design Therapeutics, Inc. (Nasdaq: DSGN) announced the initiation of patient dosing in a Phase 1 multiple ascending dose (MAD) clinical ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE